Shares of FibroGen, Inc. (NASDAQ:FGEN) climbed about 3% on Monday after the company said its drug candidate roxadustat has ...

Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ...

Investing.com -- FibroGen, Inc. (NASDAQ:FGEN) stock rose 3% Monday after the company announced that its drug roxadustat received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA ...

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025SAN FRANCISCO, (GLOBE NEWSWIRE) -- FibroGen, Inc.

We recently published 13 Best ADR Stocks to Invest In. GSK plc (NYSE:GSK) is one of the best ADR stocks. GSK plc (NYSE:GSK) ...

FibroGen (FGEN) announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted roxadustat Orphan Drug Designation for the treatment of myelodysplastic ...

As orphan drugs account for an increasing share of drugs approved, they are driving up the cost of drug launches and drug prices. In a new paper, America's Health Insurance Plans analyzes these rising ...

AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE MYELOID ...

The Orphan Drug Act (ODA) came into effect in 1983 as a solution to meet an unmet need in the industry. Its success is often projected as an example of how innovative regulatory frameworks can be used ...

Last month, the Food and Drug Administration took the unusual step of admitting it had made a mistake 25 years ago when it granted orphan drug status to an opioid addiction treatment called ...

The Orphan Drug Act of 1983 was passed to promote the development of rare disease treatments. To qualify for incentives under the act, sponsors must first receive “orphan drug designation” from the ...